Patient P-02165

Synthetic patientMETA-24 · Day 107 · 45–54 · F · baseline S14Open companion preview

Therapy response

Stable

Tolerance

Deteriorating

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

74%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 69 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 73 GI-04 recommended — GI Support Protocol GI-04
Day 74 Patient accepted — Started GI-04 in the companion
Day 81 ME-01 recommended — Monitoring Escalation ME-01
Day 82 No meaningful change — GI Support Protocol GI-04
Day 82 Patient accepted — Started ME-01 in the companion
Day 85 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 69.

Primary contributors, last 14 days

Treatment adherence-21
GI instability-9
Nutritional resilience+8
Toxicity+5
Inflammatory activity+3

What helped?

GI Support Protocol GI-04Day 73
Result: no meaningful change
Monitoring Escalation ME-01Day 81
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Supportive Compound SC-12

69%

probability of meaningful tolerance improvement

284 similar trajectories
75% showed improvement
median effect visible after 6 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 66 and rising
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 33/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 64
- WearableHRV 36 ms, trending down
Drug metabolism and exposure ↑20
- BloodToxicity index 53
Autonomic recovery ↓20
- Wearable2,365 steps/day

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity

Microbiome

Shannon diversity 2.4 · butyrate capacity 33/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 37 ms
Sleep: 6.4 h
Steps: 2,458
Resting HR: 71 bpm

Daily log: GI score 66, nutritional resilience 39, adherence 57.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02508	50%	S14	ME-01	improved	51
P-02401	41%	S14	GI-04	improved	49
P-02666	41%	S14	ME-01	improved	51
P-02106	40%	S14	GI-04	improved	44
P-02381	40%	S14	SC-12	improved	52
P-02094	39%	S14	NP-02	improved	53
P-02236	39%	S14	GI-04	improved	45
P-02316	39%	S14	GI-04	improved	51
P-02348	39%	S14	GI-04	improved	49
P-02018	38%	S01	GI-04	improved	46
P-02060	37%	S14	GI-04	improved	54
P-02132	37%	S14	SC-12	improved	40